Abbott Laboratories ABT
103.87 USD -0.61 (-0.58%)
Regular-session close
103.87 0.00 0.00%
After hours · Nov 19, 4:07 PM ET
103.61 Day range 105.83
81.97 52-week range 129.85
- YTD
- -17.10%
- 1 year
- -17.66%
News
fool.com 3 Dividend Kings to Buy in November and Never Sell Abbott boasts 54 straight years of dividend growth, and plans to spin off its troubled nutrition division could lead to a re-rating of the stock. McDonald's has raised its dividend for 50 years, and…benzinga.com Abbott Initiates VOYAGER CE Clinical Trial Evaluating Investigational Encantor Transcatheter Aortic Valve Implantation Software-Guided Balloon-Expandable System For Treating Symptomatic Severe Aortic Stenosis Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve
prnewswire.com Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve…
benzinga.com This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Wall Street analysts upgraded RGA, BRO, ABT, FMX and MRSH, raising price targets and outlooks across reinsurance, insurance, healthcare and beverages.benzinga.com Leerink Partners Upgrades Abbott Laboratories to Outperform, Announces $124 Price Target Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.
benzinga.com Ken Griffin Dumps SpaceX, Amazon; Buys ARKK and Bets Big on Marvell Inside Citadel's Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner's AI fund.
seekingalpha.com The Winners Inside SCHD - November 2026 The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have…
zacks.com Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026 ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.
gurufocus.com Is ABT Overvalued? DCF Says Worth $76 On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a
defenseworld.net 11,649 Abbott Laboratories $ABT Shares Bought by AlTi Global Inc. AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange…
defenseworld.net Abbott Laboratories $ABT Stock: Allworth Financial LP Increases Position Allworth Financial LP raised its holdings in Abbott Laboratories (NYSE: ABT) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).…
zacks.com Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings? ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.
defenseworld.net CenterBook Partners LP Acquires New Shares in Abbott Laboratories $ABT CenterBook Partners LP bought a new position in shares of Abbott Laboratories (NYSE: ABT) during the third quarter, according to its most recent disclosure with the Securities and Exchange…
benzinga.com Abbott Touts Favorable Outcomes In Cardiovascular Device Trials Abbott reports positive trial results for its Amulet 360 LAA occluder and SonicForce coronary IVL system at a conference.benzinga.com Abbott Announces One-Year Results For Its Amulet 360 Left Atrial Appendage Occluder From The VERITAS Study; Data Show Meaningful Closure Rates Of Left Atrial Appendage And A Low Incidence Of Stroke In People With Atrial Fibrillation Not Caused By A Heart Valve Issue The data were presented in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., on Nov. 1, 2026, and simultaneously published in JACC:…
benzinga.com Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary…
benzinga.com Abbott Initiates CROWN-MV Pivotal Trial Evaluating Safety And Effectiveness Of Its Investigational Cephea Mitral Valve System For Symptomatic Mitral Valve Disease CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for…
benzinga.com This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.benzinga.com Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular…
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
benzinga.com Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect®…
benzinga.com Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122 Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.
benzinga.com RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125 RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $112 to $119.
benzinga.com JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118 JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
benzinga.com TD Cowen Maintains Buy on Abbott Laboratories, Lowers Price Target to $118 TD Cowen analyst Joshua Jennings maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $118.
benzinga.com Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123 Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.
benzinga.com BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125 BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
benzinga.com Abbott CEO Rules Out Selling $8.5 Billion Nutrition Business: 'No Interest' Abbott (ABT) to spin off its $8.5B nutrition arm, makers of Ensure & Similac, by end of 2027. Stock dips following Q3 results.
benzinga.com Meta, Tesla On Deck Wednesday As AI Spending, Auto Demand Face Test Meta Platforms and Tesla headline Wednesday’s reports, with investors focused on whether AI investment can keep driving growth while Tesla’s core auto business weakens. Philip Morris International,…
benzinga.com Abbott Laboratories Q3 2026 Earnings Call Transcript Abbott Laboratories (NYSE:ABT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Abbott Laboratories Narrows FY2026 Adj EPS Guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 Est Abbott Laboratories (NYSE:ABT) narrows FY2026 Adj EPS guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 analyst estimate..
benzinga.com Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $1.42 per share which met the analyst consensus estimate. This is a 9.23 percent increase over earnings of $1.30 per share from the same…
benzinga.com Abbott To Spin Off Nutrition Business Into Independent Public Company With $8.5B In Annual Sales; Separation Expected To Be Completed By 2027 End Separation will unlock potential of both companies to pursue distinct growth and value-creation strategiesThe new Nutrition company will be a global leader in the rapidly growing healthy nutrition…
benzinga.com How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings Abbott expects Q3 EPS of $1.41 and $12.99B revenue. Its 2.42% dividend requires about $247,767 invested to generate $500 monthly.
benzinga.com Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings Abbott reports Q3 earnings Oct. 21; analysts expect $1.41 EPS and $12.99B revenue. FDA approved CardioMEMS updates.economies.com SAFCO Stock Price - 2020 Economies.com provides you with SAFCO share price (2020) listed in the stock exchange, including the low, high, opening and closing price. In addition, we provide you with news for the listed company…
nbcnews.com Texas Governor Results 2026 The Texas Governor race has shifted 20.81 points toward Democrats compared with the 2024 presidential election. See the county-by-county breakdown below. Shift to Democrats Shift to Republicans Arrow…
finance.yahoo.com If You Ran Abbott, What Would You Do? If you ran Abbott Laboratories (ABT), you would start with how little of each sale it keeps as profit. The business is ...
tradersunion.com Abbott introduces two-in-one glucose ketone sensor: Can ABT recover above the MA-50? Abbott stock edges lower, trading at $103.82 today, while the company unveils dual glucose and ketone sensing technology.
cnbc.com Here are Thursday's biggest analyst calls: Nvidia, Anthropic, SpaceX, Apple, Abbott Labs, Box, Strategy & more Wolfe initiates Anthropic as outperform Wolfe said Anthropic is "best-in-class." "With the largest TAM, the fastest growth, the most social impact, and a path to add more revenue in CY28 than any ...
finance.sina.com.cn 雅培收跌0.22%,成交额7.29亿美元 11月19日,雅培(ABT)收跌0.22%,报104.48美元,成交额7.29亿美元,市值1809.53亿美元。 公司最新财报显示,季度营收130.13亿美元,同比增长14.46%。 公司简介 雅培(Abbott Laboratories)公司于1888年在美国芝加哥由雅培医生创办,公司历经百年发展,如今的雅培公司已发展成今天一个医药及营养产品多元化的世界…
seekingalpha.com MedTech poised to outperform in 2027, Leerink says as Abbott upgraded Abbott Laboratories (ABT) stock gains as Leerink Partners to Outperform from Market Perform, citing significant gains ahead ...
finance.yahoo.com Point-of-Care/Rapid Diagnostics - Global Strategic Business Report 2026: Capture a $40.7 Billion Market by 2032 with Abbott, Roche, Danaher and Siemens Care/Rapid Diagnostics - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global point-of-care/rapid diagnostics market was valued at US$26.1 billion in…
finance.yahoo.com How Much Did Medtronic Stock Really Pay Its Holders? Could Anthropic Stock Fall 25%? Medtronic (MDT) makes medical devices ranging from heart products in its Cardiovascular ...
finance.yahoo.com Abbott Laboratories (ABT) Starts VOYAGER CE Trial With New Encantor TAVI System Abbott Laboratories (NYSE:ABT) has launched its software-guided, balloon-expandable Encantor TAVI system for structural heart ...
finance.yahoo.com Global Point-of-Care Connectivity Solutions Market to Reach $1.7 Billion by 2032 | Abbott, Roche, Siemens Healthineers and GE HealthCare Accelerate AI-Driven Care Care Connectivity Solutions - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global point-of-care connectivity solutions market was valued at US$1.1…
finance.yahoo.com Nerve Repair and Regeneration Devices - Global Strategic Business Report: Secure Share of a $17.6B Market by 2030 as Abbott, Boston Scientific, Collagen Matrix and Inspire ... Identify revenue opportunities with insights into tariffs, regional shifts, competitive positioning, and innovations in biomaterials, stem cells, and 3D printing.Dublin, Nov. 19, 2026 (GLOBE…
